Cutaneous adverse reactions to monoclonal antibody treatments;Réactions cutanées indésirables des traitements par anticorps monoclonaux

Revue Medicale de Liege

Volumn 64, Issue 5-6, 2009, Pages 339-346

  Pierard Franchimont C ^a,b   Pierard G E ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Centre Hospitalier Hutois   (Belgium)

Author keywords

CD20; CD52; Drug reaction; EGF; TNF ; VEGF

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; BASILIXIMAB; BENZOYL PEROXIDE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACLIZUMAB; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; ERYTHROMYCIN; ETANERCEPT; GEFITINIB; INFLIXIMAB; IRINOTECAN; ISOTRETINOIN; METHOTREXATE; METRONIDAZOLE; MONOCLONAL ANTIBODY; OMALIZUMAB; PACLITAXEL; PALIVIZUMAB; RETINOID; RITUXIMAB; SORAFENIB; SUNITINIB; TETRACYCLINE; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG;

ACNE; ALOPECIA; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; BRONCHUS CANCER; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; CONJUNCTIVITIS; DEPIGMENTATION; DIGESTIVE SYSTEM PERFORATION; DRUG EFFECT; ERYTHEMA; EXFOLIATIVE DERMATITIS; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HUMAN; HYPERSENSITIVITY; HYPERSENSITIVITY REACTION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INJECTION SITE REACTION; KERATODERMA; METASTASIS; MORBIDITY; NEVUS; PHOTOSENSITIVITY; PROGNOSIS; PRURITUS; QUALITY OF LIFE; RASH; RECOGNITION; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; STOMATITIS; SUBCUTANEOUS HEMORRHAGE; THROMBOEMBOLISM; URTICARIA; XEROSIS;

ANTIBODIES, MONOCLONAL; DRUG ERUPTIONS; HUMANS;

EID: 67749137406     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Agero ALC, Dusza SW, Benvenuto-Andrade C, et al.- Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol, 2006, 55, 657-670. (Pubitemid 44436627)
2. Piérard-Franchimont C, Blaise G, Paquet P, et al.- Acné iatrogène paroxystique et les inhibiteurs du facteur de croissance épidermique (EGFR). Rev Med Liège, 2007, 62, 11-14.
3. Salama JK, Seiwert TY, Vokes EE.- Chemoradiotherapy for locally advanced head and neck cancer. J Clin Oncol, 2008, 135, 148-153.
4. Bonner JA, Ang K.- More on severe cutaneous reaction with radiotherapy and cetuximab. N Engl J Med, 2007, 357, 1872-1873. (Pubitemid 350044823)
5. Harari PM, Allen GW, Bonner JA.- Biology of interactions : antiepidermal growth factor receptor agents. J Clin Oncol, 2007, 25, 4057-4065. (Pubitemid 47492950)
6. Marty M, Cognetti F, Maranincki D, et al.- Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human EGFR2 positive metastatic breast cancer administered as first line treatment. J Clin Oncol, 2005, 23, 4265-4274. (Pubitemid 46207001)
7. Cohen AD, Mermershtain W, Geffon DB, et al.- Cutaneous photosensitivity induced by paclitaxel and trastuzumab therapy associated with aberrations in the biosynthesis of porphyrins. J Dermatol Treat, 2005, 16, 19-21. (Pubitemid 40283319)
8. Autier J, Mateus C, Wechsler J, et al.- Effets secondaires cutanés de sorafénib et du sunitinib. Ann Dermatol Venereol, 2008, 135, 148-153. (Pubitemid 351625321)
9. Lee HH, Song IH, Friedrich M, et al.- Cutaneous sideeffects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol, 2007, 156, 486-491. (Pubitemid 46253946)
10. Ramos-Casals M, Brito-Zerón P, Muñoz S, et al.- Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine, 2007, 86, 242-251. (Pubitemid 47067483)
11. Tutar E, Ekici F, Naçar N, et al.- Delayed maculopapular, urticarial rash due to infliximab in two children with systemic onset juvenile idiopathic arthritis. Rheumatology, 2004, 43, 674-675. (Pubitemid 38628208)
12. Vergara G, Silvestre JF, Betlloch I, et al.- Cutaneous drug eruption to infliximab : report of 4 cases with an interface dermatitis pattern. Arch Derm, 2002, 138, 1258-1259. (Pubitemid 35025713)
13. Ettefagh L, Nedorost S, Mirmirani P.- Alopecia areata in a patient using infliximab : new insights into the role of tumor necrosis factor on human hair follicles. Arch Derm, 2004, 140, 1012. (Pubitemid 39062659)
14. Ranganathan P.- Infliximab-induced scleredema in a patient with rheumatoid arthritis. J Clin Rhem, 2005, 11, 319-322. (Pubitemid 44384023)
15. Gilaberte Y, Coscojuela C, Vázquez C, et al.- Perforating folliculitis associated with tumour necrosis factoralpha inhibitors administered for rheumatoid arthritis. Br J Dermatol, 2007, 156, 368-371. (Pubitemid 46095968)
16. Deng A, Harvey V, Sina B, et al.- Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Arch Derm, 2006, 142, 198-202. (Pubitemid 43276531)
17. Bongartz T, Sutton AJ, Sweeting MJ, et al.- Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA, 2006, 295, 2275-2285. (Pubitemid 43736578)
18. Curtis JR, Patkar N, Xie A, et al.- Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum, 2007, 56, 1125-1133. (Pubitemid 46608637)
19. Lee HH, Song IH, Friedrich M, et al.- Cutaneous sideeffects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol, 2007, 156, 486-491. (Pubitemid 46253946)
20. Asano Y, Kano Y, shiohara T.- Atypical cutaneous tuberculosis in a patient with rheumatoid arthritis treated with infliximab. Acta Derm Venereol, 2008, 88, 183-184.
21. Bergstrom L, Yocum DE, Ampel NM, et al.- Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum, 2004, 50, 1959-1966. (Pubitemid 38725108)
22. Fabre S, Gibert C, Lechiche C, et al.- Primary cutaneous Nocardia otitidiscaviarum infection in a patient with rheumatoid arthritis treated with infliximab. J Rheum, 2005, 32, 242-243. (Pubitemid 41780660)
23. Dixon WG, Watson K, Lunt M, et al.- Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy : results from the British Society for Rheumatology Biologics Register. Arth Rheum, 2006, 54, 2368-2376. (Pubitemid 44204996)
24. Smith KJ, Skelton HG.- Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. JAAD, 2001, 45, 953-956. (Pubitemid 33096643)
25. Esser AC, Abril A, Fayne S, Doyle JA.- Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab. JAAD, 2004, 50, S75-S77. (Pubitemid 38580526)
26. Lebwohl M, Blum R, Berkowitz E, et al.- No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years. Arch Derm, 2005, 141, 861-864. (Pubitemid 41058067)
27. Bovenschen HJ, Tjioe M, Vermaat H, et al.- Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals. Br J Derm, 2006, 154, 880-884.
28. Tximberidou AM, Giles FJ, Duvic M, Kurzrock R.- Pilot study of etanercept in patients with relapsed cutaneous T cell lymphomas. J Am Acad Dermatol, 2004, 51, 200-204.
29. Passarini B, Infusino SD, Barbieri E, et al.- Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy. Dermatology, 2007, 215, 295-300. (Pubitemid 47519257)
30. Wollina U, Hansel G, Koch A, et al.- Tumor necrosis factor-(alpha) inhibitor-induced psoriasis or psoriasiform exanthemata : first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol, 2008, 9, 1-14.
31. Gellrich S, Muche JM, Wilks A, et al.- Systemic eight cycle anti CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas - an applicational observation. Br J Dermatol, 2005, 153, 167-173. (Pubitemid 41044544)
32. Perez-Gala S, Delgado-Jimenez Y, Goirez R, et al.- Cytokine-release syndrome related to rituximab limited to lesions and excision scars of lesions of primary cutaneous lymphoma. Arch Dermatol, 2006, 142, 1516-1517. (Pubitemid 44790658)
33. Lowndes S, Darby A, Read G, Lister A.- Stevens Johnson syndrome after treatment with rituximab. Ann Oncol, 2002, 13, 1948-1950. (Pubitemid 36040785)
34. Fogary GB, Bayne M, Bedford P, et al.- Three cases of activation of cutaneous squamous cell carcinoma during treatment with prolonged administration of rituximab. Clin Oncol (R. Coll Radiol), 2006, 18, 155-156. (Pubitemid 43169149)
35. Puechal X, Rivereau P, Vinchon F.- Churg-Strauss syndrome associated with omalizumab. Eur J Intern Med, 2008, 19, 364-366. (Pubitemid 351783388)